Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies ( p = 0.006 ) , although no differences in MAGE were found based on HbA1c values .
These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients .
Glycemic variability ( GV ) has been an emerging target for preventing complications related to type 2 diabetes .
For reducing GV , DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs ( OADs ) , but systematic evaluation has yet to be existed .
Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride
Abstract Aims / Introduction Dipeptidyl peptidase‐4 inhibitors might have pleiotropic protective effects on cardiovascular disease ( CVD ) , in contrast to sulfonylureas . Therefore , we compared various CVD risk factors between vildagliptin and glimepiride . Material s and Methods We carried out a r and omized , prospect i ve and crossover trial . A total of 16 patients with type 2 diabetes whose glycated hemoglobin was > 7 % were r and omized to add vildagliptin or glimepiride .  After 12‐week treatment , each drug was replaced with the other for another 12 weeks . Before and after each treatment , glucose homeostasis and CVD risk factors were assessed , and the continuous glucose monitoring system was applied to calculate glycemic variability . Results The mean age of the participants was 60 years , 31 % were men , body mass index 25.5 kg/m2 and HbA1c 8.41 % .  Both vildagliptin and glimepiride significantly decreased glycated hemoglobin and glycemic variability indices . Despite the improved glucose homeostasis , favorable change of CVD markers was not prominent in both the arms , along with significant weight gain . Only plasma stromal cell‐derived factor (SDF)‐1α decreased by 30 % in the vildagliptin arm . According to regression analyses , the reduction of SDF‐1α was independently associated with vildagliptin usage and serum interleukin‐6 changes , but white blood cells were not related with the SDF‐1α changes . Conclusion Compared with glimepiride , vildagliptin arrestingly decreased plasma SDF‐1α , and its clinical implication s should be further investigated
Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies ( p = 0.006 ) , although no differences in MAGE were found based on HbA1c values .
These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients .
Glycemic variability ( GV ) has been an emerging target for preventing complications related to type 2 diabetes .
For reducing GV , DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs ( OADs ) , but systematic evaluation has yet to be existed .